[1]王昊德王海银金春林符雨嫣孙辉许明飞.诊断技术评估方法及应用研究[J].中国卫生质量管理,2022,29(06):013-17.[doi:10.13912/j.cnki.chqm.2022.29.6.04 ]
　WANG Haode,WANG Haiyin,JIN Chunlin.Method and Application of Diagnostic Technology Assessment[J].Chinese Health Quality Management,2022,29(06):013-17.[doi:10.13912/j.cnki.chqm.2022.29.6.04 ]
点击复制

诊断技术评估方法及应用研究
分享到：

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第29卷
期数:
2022年06期
页码:
013-17
栏目:
特别关注
出版日期:
2022-06-28

文章信息/Info

Title:
Method and Application of Diagnostic Technology Assessment
作者:
王昊德王海银金春林符雨嫣孙辉许明飞
上海市卫生和健康发展研究中心
Author(s):
WANG Haode; WANG Haiyin; JIN Chunlin
Shanghai Health Development Research Center
关键词:
卫生技术评估; 诊断技术; 评估方法; 肝性脑病; 血氨诊断
Keywords:
Health Technology Assessment (HTA); Diagnostic Techniques;  Evaluation Methods;  Hepatic Encephalopathy;  Blood Ammonia Test
分类号:
R197.323
DOI:
10.13912/j.cnki.chqm.2022.29.6.04
文献标志码:
A
摘要:
诊断技术评估有助于充分了解新技术价值，进一步优化临床资源配置。在梳理层次分析和决策理论、逐步评估理论、多准则决策分析理论、检测-治疗价值评估理论四大主要诊断技术评估方法的基础上，以两种急诊肝性脑病血氨诊断方法的评估为例，阐述了检测-治疗价值评估理论模型的应用价值。建议研究者基于具体问题选择适合的评估模型，政策决策者制定诊断产品的HTA指南，助推我国诊断技术HTA的标准化发展。
Abstract:
Diagnostic technology assessment can help fully understand the value of new technologies and further optimize the allocation of clinical resources. Based on the four main HTA methods of hierarchical analysis and decision theory, stepwise evaluation theory, multi-criteria decision analysis theory, test and treatment value assessment theory, the evaluation of two diagnostic methods of blood ammonia in emergency hepatic encephalopathy was taken as an example, it expounded the application value of the test and treatment value assessment theoretic model. It was suggested that researchers chose appropriate assessment models based on specific problems, and policy makers formulated HTA guidelines for diagnostic products to promote the standardized development of diagnostic technology HTA in China.

参考文献/References:

［1］王海银,张晓溪,房良,等.我国卫生技术评估流程规范研究［J］.中国卫生质量管理,2016,23(6):60-63. ［2］VAN DA, CLEEMPUT I, AERTGEERTS B, et al. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed［J］. Journal of Clinical Epidemiology, 2007, 60(11):1116-1122. ［3］POLISENA J,CASTALDO R,CIANI O,et al. Health technology assessment methods guidelines for medical devices: how can we address the gaps? The international federation of medical and biological engineering perspective ［J］. International Journal of Technology Assessment in Health Care, 2018，34(3)：276-289. ［4］AUGUSTOVSKI F, ALFIE V, ALCARAZ A, et al. A value framework for the assessment of diagnostic technologies: a proposal based on a targeted systematic review and a multistakeholder deliberative process in Latin America［J］. Value in Health, 2021,24（4）： 486-496. ［5］BOGAVAC-STANOJEVI N. Economic evaluation as a tool in emerging technology assessment［J］. EJIFCC, 2018, 29(3):196-200. ［6］CALLEN J, GEORGIOU A, LI J, et al. The safety implications of missed test results for hospitalised patients: a systematic review［J］. BMJ Quality & Safety, 2011, 20(2):194-199. ［7］YANG Y, ABEL L, BUCH-ANAN J, et al. Use of decision modelling in economic evaluations of diagnostic tests: an appraisal and review of health technology assessments in the UK［J］. PharmacoEconomics - Open, 2019,3(3):281-291. ［8］GARFIELD S, POLISENA J, SPINNER SS, et al. Health technology assessment for molecular diagnostics: practices,challenges,and recommendations from the medical devices and diagnostics special interest group［J］.Value in Health:the Journal of the International Society for Pharmacoeconomics and Outcomes Research, 2016,19(5):577-587. ［9］LEDLEY RS, LUSTED LB. Reasoning foundations of medical diagnosis: symbolic logic, probability, and value theory aid our understanding of how physicians reason［J］. Science, 1959, 130(3366):9-21. ［10］SACKETT DL, HAYNES RB. The architecture of diagnostic research［J］. BMJ(Clinical Research ed.),2002,324(7336):539-541. ［11］BOGAVAC-STANOJEVI N,JELIC-IVANOVIC I. The cost-effective laboratory: implementation of economic evaluation of laboratory testing［J］. Journal of Medical Biochemistry, 2017, 36(3):238-242. ［12］PHELPS CE, MUSHLIN AI. Focusing technology assessment using medical decision theory［J］. Medical Decision Making:an International Journal of the Society for Medical Decision Making, 1988, 8(4):279-289. ［13］SOARES M, WALKER S,PALMER SJ, et al. Establishing the value of diagnostic and prognostic tests in health technology assessment［J］. Medical Decision Making:an International Journal of the Society for Medical Decision Making, 2018, 38(4):495-508. ［14］TOMAIUOLO R, DERRICO P, RITROVATO M, et al. COVIDIAGNOSTIX : health technology assessment of serological tests for SARS-CoV-2 infection［J］. International Journal of Technology Assessment in Health Care, 2021, 37(1):e87. ［15］鲍海妮,余小兰,耿劲松,等.医药卫生领域多准则决策分析的方法学［J］.中国卫生资源,2020,23(4):337-341,372. ［16］Medical Services Advisory Committee, Department of Health and Ageing. Guidelines for the assessment of diagnostic technologies［EB/OL］.［2020-11-06］.http://www.msac.gov.au/internet/msac/publishing.nsf/. ［17］任占宝, 王金英. 两种方法测定血氨分析性能的比较与评价［J］. 继续医学教育, 2013, 27(5):55-58. ［18］赵文新, 王 英. 诊断血样凝血溶血常见原因及对策分析［J］. 中外医疗, 2009(13):152. ［19］李乐辉, 吴国平, 林 润. 血清 Trp 联合血氨检测提高急诊 ICU 肝性脑病早期诊断灵敏度的临床价值［J］. 肝脏, 2019, 24(4):415-417. ［20］中华医学会消化病学分会, 中华医学会肝病学分会. 中国肝性脑病诊治共识意见(2013 年,重庆)［J］. 中华消化杂志, 2013, 33(2):81-93. ［21］上海市物价局，上海市卫生局，上海市医保办 . 上海市医疗机构医疗服务项目和价格汇编（ 2017 年 9 月）［ EB/OL］.［2020-11-06］.https://wsjkw.sh.gov.cn/ylsfbz/index.html. ［22］熊 凯. 2016-2018年我院乙型肝炎肝硬化住院患者住院费用分析［J］. 中国社区医师, 2019, 35(12):190-191. ［23］刘国恩.中国药物经济学评价指南 2020［M］.北京：中国市场出版社，2020：14. ［24］中华医学会肝病学分会.肝硬化肝性脑病诊疗指南［J］.中华肝脏病杂志,2018,26(10):721-736. ［25］刘文彬,陈英耀,茅艺伟,等. 我国卫生技术评估研究质量影响因素的定性研究［J］. 中国卫生质量管理,2015,22(2):87-90. ［26］黄艳玲，唐欣芝，周如华，等. 心力衰竭临床决策支持系统临床应用效果分析［J］.中国卫生质量管理,2021,28(11):29-33.

相似文献/References:

[1]唐檬,陈英耀,茅艺伟,等.中国卫生技术评估决策转化现状及影响因素的定性研究[J].中国卫生质量管理,2015,22(06):095.
[2]王海银 张晓溪 房良 金春林.我国卫生技术评估流程规范研究[J].中国卫生质量管理,2016,23(06):060.[doi:10.13912/j.cnki.chqm.2016.23.6.21]
[3]魏巍 张涛 鱼敏.便携式早期清创冲洗器的卫生技术评估[J].中国卫生质量管理,2018,25(03):079.[doi:10.13912/j.cnki.chqm.2018.25.3.24]
[4]张曙欣 陈校云 冯力 宋杨杨 胡可慧 黄婉茹 裴治纲.澳大利亚和新西兰新兴卫生技术水平扫描网络的实践与启示[J].中国卫生质量管理,2019,26(02):106.[doi:10.13912/j.cnki.chqm.2019.26.2.31]
[5]孙辉 金春林 程文迪 房良 王海银.西班牙卫生技术评估的发展应用及启示[J].中国卫生质量管理,2019,26(03):106.[doi:10.13912/j.cnki.chqm.2019.26.3.29]
[6]王海银 丛郦萱 彭颖 王美凤 金春林.我国新医疗技术的定价及支付优化策略探讨[J].中国卫生质量管理,2020,27(01):105.[doi:10.13912/j.cnki.chqm.2020.27.1.27]
[7]程文迪 孙辉 房良 王海银.泰国卫生技术评估机制建设现状及启示[J].中国卫生质量管理,2020,27(01):109.[doi:10.13912/j.cnki.chqm.2020.27.1.28]
[8]邱英鹏赵翔肖月赵羽西.高值医用耗材定义与治理内涵研究[J].中国卫生质量管理,2021,28(05):001.[doi:10.13912/j.cnki.chqm.2021.28.5.01 ]
　QIU Yingpeng,ZHAO Xiang,XIAO Yue.The Definition and Governance Connotation of High Value Medical Consumables[J].Chinese Health Quality Management,2021,28(06):001.[doi:10.13912/j.cnki.chqm.2021.28.5.01 ]
[9]赵羽西邱英鹏肖月.英国高值医用耗材准入及招采管理经验分享：以英格兰为例[J].中国卫生质量管理,2021,28(05):008.[doi:10.13912/j.cnki.chqm.2021.28.5.03 ]
　ZHAO Yuxi,QIU Yingpeng,XIAO Yue.Access and Procurement Management of High Value Medical Consumables in the UK: A Case Study of England[J].Chinese Health Quality Management,2021,28(06):008.[doi:10.13912/j.cnki.chqm.2021.28.5.03 ]
[10]邱英鹏赵羽西赵翔肖月.澳大利亚假体类高值医用耗材医保准入管理经验及启示[J].中国卫生质量管理,2021,28(05):012.[doi:10.13912/j.cnki.chqm.2021.28.5.04 ]
　QIU Yingpeng,ZHAO Yuxi,ZHAO Xiang.Experience in Medical Insurance Access Management of Prosthetic High Value Medical Consumables in Australia and Its Implications[J].Chinese Health Quality Management,2021,28(06):012.[doi:10.13912/j.cnki.chqm.2021.28.5.04 ]

更新日期/Last Update: 2022-06-28